Developer docs
API playgroundTry for free, no card

Search company profiles

Aprogen Pharmaceuticals

Full company profile

uuid0004fqq

Namestring
Aprogen Pharmaceuticals
Company typeenum
Private
Founded yearint
1960
Short descriptiontext

Aprogen Pharmaceuticals is a South Korea-based, privately-held pharmaceutical manufacturer established in 1960 that produces and sells anti-cancer drugs and digestive aid medicines, employing 251-500 staff at its Seongnam operations.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
pharmaceutical manufacturing, anti-cancer drugs, digestive medicine, biologic drugs, drug formulation
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Manufacturing
No data
Cost components5 values
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aprogen Pharmaceuticals manufactures and sells pharmaceutical products, with a portfolio that includes anti-cancer drugs and digestive aid medicines. The company develops and produces drug formulations serving therapeutic areas in oncology and gastroenterology, with manufacturing operations based in Seongnam, South Korea, and a biologics drug development arm.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Anti-cancer drugs
CategoryOncology pharmaceuticals
Description

Manufactured pharmaceutical products used in oncology treatment, sold to healthcare providers, hospitals, and pharmaceutical distributors.

2Digestive aid medicine
CategoryGastroenterology pharmaceuticals
Description

Manufactured gastrointestinal pharmaceutical formulations sold to healthcare providers, hospitals, and pharmaceutical distributors.

No data
Peers10 records
TypeEmerging player
Description

Korean biopharmaceutical leader focused on biosimilars and biologics. Comparable given Aprogen's separate biologics platform (aprogen-biologics.com) and overlapping specialty/biologics development ambitions in Korea.

TypeBroad incumbent
Description

World-scale Korean biologics contract manufacturer. Comparable as a domestic biologics manufacturing capability alternative, particularly relevant as Aprogen expands its biologics platform.

TypeBroad incumbent
Description

One of the largest Korean pharmaceutical companies, spanning prescription drugs, OTC, and consumer health (digestive care). Comparable given Aprogen's digestive-aid and specialty pharma positioning within the same Korean industry.

TypeBroad incumbent
Description

Korean biopharma with vaccines, plasma products, and specialty therapeutics. Comparable as a domestic competitor with biologics manufacturing breadth intersecting Aprogen's pharmaceutical and biologics activities.

TypeDirect peer
Description

Mid-to-large Korean pharmaceutical manufacturer with a mix of prescription, OTC, and consumer health products including GI-related offerings. Comparable as a Korea-based pharma competitor overlapping in primary-care/digestive categories.

TypeBroad incumbent
Description

Established Korean pharmaceutical manufacturer with a domestic + international generics and specialty footprint. Comparable as a Korea-headquartered pharma manufacturer competing in similar therapeutic and commercial channels.

TypeBroad incumbent
Description

Major South Korean specialty pharma firm with oncology and specialty-care drug development. Comparable as a domestic Korean pharma competitor operating in specialty and primary care categories where Aprogen also competes.

TypeDirect peer
Description

Korean pharmaceutical company with a primary-care and specialty product mix including GI and related therapeutic categories. Comparable as a mid-sized Korean peer competing for similar domestic distribution and prescription share.

9LG Chem Life Sciences
TypeEmerging player
Description

Korean life-sciences business investing in specialty and biologics pipelines. Comparable as a domestic Korea-based player expanding into specialty therapeutics and biologics, the same categories where Aprogen is increasing exposure.

10Nichi-Iko Pharmaceutical
TypeDirect peer
Description

Japan's largest generic pharmaceutical manufacturer and a strategic investor in Aprogen via multiple funding rounds. Highly comparable in generics-and-specialty-pharma manufacturing, and the lead-buyer relationship signals overlapping customer channels and product mix.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aprogen Pharmaceuticals

Pharmaceutical Manufacturingaprogen-pharm.com

Aprogen Pharmaceuticals is a South Korea-based, privately-held pharmaceutical manufacturer established in 1960 that produces and sells anti-cancer drugs and digestive aid medicines, employing 251-500 staff at its Seongnam operations.

Aprogen Pharmaceuticals firmographics

Firmographics
Name
Aprogen Pharmaceuticals
Website
https://aprogen-pharm.com
Company type
Private
Founded year
1960
Headcount range
251–500 employees
Short description
Aprogen Pharmaceuticals is a South Korea-based, privately-held pharmaceutical manufacturer established in 1960 that produces and sells anti-cancer drugs and digestive aid medicines, employing 251-500 staff at its Seongnam operations.
Ownership category
akta.pro rank

Aprogen Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Anti-cancer drugs
  • Digestive medicine
  • Biologic drugs
  • Drug formulation

Where Aprogen Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Markets served

Aprogen Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Aprogen Pharmaceuticals product offering

Product offering

Core offering

Aprogen Pharmaceuticals manufactures and sells pharmaceutical products, with a portfolio that includes anti-cancer drugs and digestive aid medicines. The company develops and produces drug formulations serving therapeutic areas in oncology and gastroenterology, with manufacturing operations based in Seongnam, South Korea, and a biologics drug development arm.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anti-cancer drugs Manufactured pharmaceutical products used in oncology treatment, sold to healthcare providers, hospitals, and pharmaceutical distributors.
  • Digestive aid medicine Manufactured gastrointestinal pharmaceutical formulations sold to healthcare providers, hospitals, and pharmaceutical distributors.

Companies that use Aprogen Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Aprogen Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aprogen Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • Celltrion: Korean biopharmaceutical leader focused on biosimilars and biologics. Comparable given Aprogen's separate biologics platform (aprogen-biologics.com) and overlapping specialty/biologics development ambitions in Korea.
  • LG Chem Life Sciences: Korean life-sciences business investing in specialty and biologics pipelines. Comparable as a domestic Korea-based player expanding into specialty therapeutics and biologics, the same categories where Aprogen is increasing exposure.

Broad incumbents

  • Samsung Biologics: World-scale Korean biologics contract manufacturer. Comparable as a domestic biologics manufacturing capability alternative, particularly relevant as Aprogen expands its biologics platform.
  • Yuhan Corporation: One of the largest Korean pharmaceutical companies, spanning prescription drugs, OTC, and consumer health (digestive care). Comparable given Aprogen's digestive-aid and specialty pharma positioning within the same Korean industry.
  • GC Biopharma (formerly Green Cross): Korean biopharma with vaccines, plasma products, and specialty therapeutics. Comparable as a domestic competitor with biologics manufacturing breadth intersecting Aprogen's pharmaceutical and biologics activities.
  • Daewoong Pharmaceutical: Established Korean pharmaceutical manufacturer with a domestic + international generics and specialty footprint. Comparable as a Korea-headquartered pharma manufacturer competing in similar therapeutic and commercial channels.
  • Hanmi Pharmaceutical: Major South Korean specialty pharma firm with oncology and specialty-care drug development. Comparable as a domestic Korean pharma competitor operating in specialty and primary care categories where Aprogen also competes.

Direct peers

  • Dong-A Pharmaceutical: Mid-to-large Korean pharmaceutical manufacturer with a mix of prescription, OTC, and consumer health products including GI-related offerings. Comparable as a Korea-based pharma competitor overlapping in primary-care/digestive categories.
  • Boryung Pharmaceutical: Korean pharmaceutical company with a primary-care and specialty product mix including GI and related therapeutic categories. Comparable as a mid-sized Korean peer competing for similar domestic distribution and prescription share.
  • Nichi-Iko Pharmaceutical: Japan's largest generic pharmaceutical manufacturer and a strategic investor in Aprogen via multiple funding rounds. Highly comparable in generics-and-specialty-pharma manufacturing, and the lead-buyer relationship signals overlapping customer channels and product mix.

Market position

Customer concentration

Aprogen Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aprogen Pharmaceuticals leadership team

Management profile

Number of profiles

Aprogen Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aprogen Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aprogen Pharmaceuticals

What does Aprogen Pharmaceuticals do?

Aprogen Pharmaceuticals manufactures and sells pharmaceutical products, with a portfolio that includes anti-cancer drugs and digestive aid medicines. The company develops and produces drug formulations serving therapeutic areas in oncology and gastroenterology, with manufacturing operations based in Seongnam, South Korea, and a biologics drug development arm.

When was Aprogen Pharmaceuticals founded?

Aprogen Pharmaceuticals was founded in 1960. It employs 251 to 500 people.

Where is Aprogen Pharmaceuticals based?

Aprogen Pharmaceuticals is headquartered in Seongnam, South Korea, in the Asia region.

Who are Aprogen Pharmaceuticals's main competitors?

Emerging players on record are Celltrion and LG Chem Life Sciences. Broad incumbents are Samsung Biologics, Yuhan Corporation, GC Biopharma (formerly Green Cross), Daewoong Pharmaceutical and Hanmi Pharmaceutical. Direct peers are Dong-A Pharmaceutical, Boryung Pharmaceutical and Nichi-Iko Pharmaceutical.

Does Aprogen Pharmaceuticals have an API?

No public API is recorded for Aprogen Pharmaceuticals.

What industry is Aprogen Pharmaceuticals in?

Aprogen Pharmaceuticals's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAprogen shareholder G-BAISE lifts stake to 84.98% from 84.08% filing showsG-BAISE raised its stake in Aprogen to 84.98% from 84.08%, holding 97,410,334 shares. The increase came from convertible bond conversion-price resets, higher share count from conversion requests, and related-party purchases. Shares under major contracts rose to 24,921,900, while the contract ratio fell to 21.74%.The future of tradingAprogen completes KRW 20 billion private convertible bond saleAprogen completed issuance of KRW 20 billion in 35th series bearer, unsecured private convertible bonds. Payment for the offering was completed on Sept. 23, 2026.AInvestThe Thirty-Third Time Is Not a Charm — It's a MachineAprogen, a South Korean biopharma firm, issued its 33rd series of convertible bonds to raise KRW 2 billion from Jade New Technology Association. This financing occurs amid significant financial distress, with the company reporting a KRW 58 billion loss in 2024 and projecting a KRW 70 billion loss for 2025. The stock has plummeted 98% from its five-year high, highlighting management's reliance on this debt instrument to avoid direct equity dilution while facing substantial conversion overhang risks.ChosunbizKorean bio corporations invest in cryptocurrency to overcome funding shortages and delisting risksBio corporations facing funding shortages and delisting risks are entering cryptocurrency ventures to secure R&D financing. Aprogen's subsidiaries and Bridge Biotherapeutics have invested in Bitcoin and other assets, while U.S. firms like MEI Pharma and Windtree Therapeutics follow similar patterns. Industry concerns remain about neglecting core drug development.ChosunbizAprogen's U.S. subsidiary shifts focus to cryptocurrency investment for R&D fundingAptneuroscience's U.S. subsidiary ApTELos has shifted its business purpose to cryptocurrency investment, using $12 million in cash to buy Bitcoin and other assets. The company plans to expand holdings and enter derivative businesses, aiming to secure R&D funding for its biosimilar and Parkinson's drug development.Yonhap News AgencyBio startup Aprogen gets S. Korea's 11th unicorn statusAprogen Pharmaceuticals was listed as South Korea's 11th unicorn with a valuation over $1 billion, per CB Insights. The company raised 20 billion won ($16.7 million) from Lindeman Asia Investment in May. It is developing biosimilars in Japan through an alliance with Nichi-Iko Pharmaceuticals.